Classification of anti-estrogens according to intramolecular FRET effects on phospho-mutants of estrogen receptor α
Open Access
- 1 May 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (5) , 1526-1533
- https://doi.org/10.1158/1535-7163.mct-06-0750
Abstract
Anti-estrogen resistance is a major clinical problem in the treatment of breast cancer. In this study, fluorescence resonance energy transfer (FRET) analysis, a rapid and direct way to monitor conformational changes of estrogen receptor α (ERα) upon anti-estrogen binding, was used to characterize resistance to anti-estrogens. Nine different anti-estrogens all induced a rapid FRET response within minutes after the compounds have liganded to ERα in live cells, corresponding to an inactive conformation of the ERα. Phosphorylation of Ser305 and/or Ser236 of ERα by protein kinase A (PKA) and of Ser118 by mitogen-activated protein kinase (MAPK) influenced the FRET response differently for the various anti-estrogens. PKA and MAPK are both associated with resistance to anti-estrogens in breast cancer patients. Their respective actions can result in seven different combinations of phospho-modifications in ERα where the FRET effects of particular anti-estrogen(s) are nullified. The FRET response provided information on the activity of ERα under the various anti-estrogen conditions as measured in a traditional reporter assay. Tamoxifen and EM-652 were the most sensitive to kinase activities, whereas ICI-182,780 (Fulvestrant) and ICI-164,384 were the most stringent. The different responses of anti-estrogens to the various combinations of phospho-modifications in ERα elucidate why certain anti-estrogens are more prone than others to develop resistance. These data provide new insights into the mechanism of action of anti-hormones and are critical for selection of the correct individual patient-based endocrine therapy in breast cancer. [Mol Cancer Ther 2007;6(5):1526–33]Keywords
This publication has 36 references indexed in Scilit:
- The Fluorescent Toolbox for Assessing Protein Location and FunctionScience, 2006
- Lessons learnt from structural studies of the oestrogen receptorBest Practice & Research Clinical Endocrinology & Metabolism, 2006
- Estrogen Receptor α and β Heterodimers Exert Unique Effects on Estrogen- and Tamoxifen-Dependent Gene Expression in Human U2OS Osteosarcoma CellsMolecular Endocrinology, 2005
- The choice of systemic adjuvant therapy in receptor-positive early breast cancerEuropean Journal Of Cancer, 2005
- Principles for modulation of the nuclear receptor superfamilyNature Reviews Drug Discovery, 2004
- Selective Estrogen Receptor Modulators 4-Hydroxytamoxifen and Raloxifene Impact the Stability and Function of SRC-1 and SRC-3 Coactivator ProteinsMolecular and Cellular Biology, 2004
- Endocrine Responsiveness and Tailoring Adjuvant Therapy for Postmenopausal Lymph Node-Negative Breast Cancer: A Randomized TrialJNCI Journal of the National Cancer Institute, 2002
- Monitoring Agonist-induced Phospholipase C Activation in Live Cells by Fluorescence Resonance Energy TransferJournal of Biological Chemistry, 2001
- Peptide Antagonists of the Human Estrogen ReceptorScience, 1999
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998